Shield Therapeutics announces the New Drug Application for Feraccru® has been accepted for filing and review by the FDA

3 Dec 2018

Shield Therapeutics plc today announces that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Feraccru®, Shield’s lead product. Under the terms of the Prescription Drug User Fee Act (PDUFA), the FDA will shortly confirm to Shield the expected target date in 2019 for completion of the NDA review and Shield will provide a further update at that time. For full details please see the press release below:

Shield Therapeutics Press Release.

Back to news